Earlier this month, the Ragon Institute welcomed leadership from Biohaven for an insightful visit and discussion with our team. Biohaven CEO Vlad Coric, MD, and board member John Childs toured the Institute and met with Bruce Walker, MD, the Ragon Institute’s founding director, to explore mutual interests and opportunities in the fields of immunology, infectious disease research, and drug development.

Biohaven, under the leadership of Coric, is a prominent publicly traded company focused on developing novel treatments for diseases with significant unmet medical needs. Their innovative approach includes developing groundbreaking therapies for rare and common diseases such as migraine, epilepsy, pain and mood disorders, and other challenging diseases. The company’s entrepreneurial, patient-centered philosophy closely aligns with the Ragon Institute’s commitment to leveraging immunology research to tackle global health challenges.

The visit included a detailed discussion with Walker, exploring shared insights at the intersection of immunology, biotechnology, and therapeutic innovation. Dr. Walker provided an overview of the Institute’s pioneering research in harnessing the immune system to prevent and cure infectious diseases. The Biohaven team, including board member John Childs, toured the Ragon’s state-of-the-art facilities and engaged in meaningful dialogue about mutual interests in innovation and patient-focused science.

This visit reinforces the value of fostering connections between academic research institutions and industry leaders to accelerate the development of life-changing therapies.

We extend our sincere appreciation to Dr. Vlad Coric, John Childs, and the entire Biohaven leadership team for their visit and look forward to potential future collaborations that could enhance our shared mission to improve global health outcomes.